Uncategorized

Merck axes Alzheimer’s study, adding to partner Neuphoria’s mounting woes

Published

on

The mid-stage disappointment in Alzheimer’s disease delivers another blow to Neuphoria Therapeutics, which in November last year was forced to launch a strategic business review after a Phase 3 trial in social anxiety disorder failed.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version